Valneva’s COVID-19 Vaccine Candidate Shows Positive Results in Phase 3 Trial
French pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read more
vaccine development
Pfizer and BioNTech Submit Initial Trial Data from COVID-19 Vaccine Phase 2/3 Study in Children to the FDA
Pfizer and BioNTech reported that data from their COVID-19 vaccine Phase 2/3 study in children aged 5 to 12 years
Read more
Pfizer-BioNTech COVID-19 Vaccine First to be Fully Approved by the FDA
The U.S. Food and Drug Administration announced on Monday it has approved the Pfizer-BioNTech COVID-19 Vaccine. The vaccine which will
Read more
Vaxzevria Highly Effective against Beta/Gamma and Delta Variants
Real-world data has shown the Vaxzevria vaccine (formerly AZD1222), co-developed by AstraZeneca, the University of Oxford and its spin-out company,
Read more
Sanofi to Invest €400 Million Annually in First-ever mRNA Vaccine Center of Excellence
Pharma giant Sanofi will spend €400 million annually towards a vaccines mRNA Center of Excellence, which will be the first
Read more
Single-dose Janssen COVID-19 Vaccine Approved in UK
The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has authorized use of the Janssen single-dose COVID-19 vaccine. The
Read more
J&J to Include Adolescents in Phase 2a of COVID-19 Vaccine Trial
Johnson & Johnson has started vaccinating teens aged 12 to 17 in the ongoing Phase 2a clinical trial for its
Read more
GSK to Support Production of Novavax’s COVID-19 Vaccine at UK Facility
GSK has made an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support the production of
Read more
J&J’s COVID-19 single-shot jab approved by the FDA for Emergency Use
The U.S. FDA has approved the first single-shot COVID-19 jab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson,
Read more
J&J’s single-dose COVID-19 vaccine offers 100% protection against hospitalisation
Johnson & Johnson announced today that the single-dose COVID-19 vaccine candidate developed by Janssen Pharmaceuticals showed 66% efficacy overall in
Read more